Spojené státy - angličtina - NLM (National Library of Medicine)

cardinal health - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg

Spojené státy - angličtina - NLM (National Library of Medicine)

avkare, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg

Kanada - angličtina - Health Canada

nu-pharm inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents

Spojené státy - angličtina - NLM (National Library of Medicine)

mckesson contract packaging - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline 400 mg

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - pentoxifylline - oral solution - 40mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - pentoxifylline - oral solution - 20mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - pentoxifylline - oral suspension - 20mg/1ml

Spojené státy - angličtina - NLM (National Library of Medicine)

bryant ranch prepack - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

Spojené státy - angličtina - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - pentoxifylline, quantity: 400 mg - tablet, modified release - excipient ingredients: povidone; hyetellose; titanium dioxide; hypromellose; erythrosine; purified talc; macrogol 8000; magnesium stearate - treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. trental 400 can thus improve function and symptoms but is not intended to replace more definitive therapy, such as vascular surgery, or removal of arterial obstructions when treating peripheral vascular disease.